PAR 12.7% 31.0¢ paradigm biopharmaceuticals limited..

Ann: Primary and Secondary endpoints met in MPS I Trial, page-33

  1. 288 Posts.
    lightbulb Created with Sketch. 79
    This MPS indication is running smoothly and a deal appears
    to be a no brainer. Well done team.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.